#Switzerland #Heart Failure #Zug #Lasix ONYU #SQ Innovation

SQ Innovation AG Enhances Leadership and Secures Financing

Introduction
SQ Innovation AG, a pioneering life-science firm based in Zug, Switzerland, has recently made headlines with two significant moves: the addition of two new members to its Board of Directors and the successful completion of Series B financing. These developments are strategically aimed at accelerating the commercial launch of Lasix® ONYU (furosemide injection), a promising treatment for worsening heart failure, in the United States.

New Board Members Join SQ Innovation

In a move set to strengthen its governance, SQ Innovation has appointed two prominent figures to its Board.
Mr. Marco van der Poel, who previously served as the CEO of GICC Holdings, Inc. and Reaxis Inc., and Mr. Erik Massmann, former CFO of Birkenstock Group B.V. Co. KG, are now part of the company’s leadership team. Their extensive experience is expected to enhance strategic direction and operational effectiveness.

They will join the existing board alongside Kevin Murphy, who became a member in November 2024 after his impressive tenure as SVP Payer Relations and Managed Care at Aetna CVS Health. The board is further led by the co-founders of SQ Innovation: Mr. Erwin Conradi, serving as the Chairman, and Dr. Pieter Muntendam, the company’s CEO.

Successful Closure of Series B Financing

Notably, SQ Innovation also announced that it has effectively closed its Series B financing, a critical step for the company’s growth. This financing, spearheaded by Mr. van der Poel, provides essential capital that will be leveraged for the U.S. commercial launch of Lasix® ONYU.

Lasix® ONYU, which has recently gained FDA approval on October 7, 2025, is set to play a crucial role in treating patients suffering from heart failure by allowing for subcutaneous administration of the drug, making it more accessible for therapeutic use.

Implications for Heart Failure Treatment

Heart failure is a significant health challenge, affecting millions globally. The approval of Lasix ONYU marks an important milestone, as it presents a new option for managing edema associated with heart failure. With enhanced board leadership and the financial backing from Series B funding, SQ Innovation is poised to make a meaningful impact on patient care in the heart failure population.

The company's focus on innovation is evident in its commitment to developing solutions that address the gaps in current treatment modalities for heart failure.

Moving Forward

SQ Innovation AG is not only solidifying its leadership structure but also charting a path forward in pioneering treatment solutions for heart failure. As the company gears up for the U.S. launch of Lasix ONYU, stakeholders are optimistic about the potential advancements in therapeutic strategies.

To explore more about SQ Innovation AG and its pioneering products, visit www.sqinnovation.com or for details on Lasix ONYU, check www.lasix-onyu.com.

Conclusion
With strong leadership and a clear vision for the future, SQ Innovation AG is set to play a pivotal role in transforming the landscape of heart failure treatment. The company is poised to deliver essential therapies that address the needs of patients, ultimately improving their quality of life and health outcomes.